Weekly Research Analysts’ Ratings Updates for Cartesian Therapeutics (RNAC)

Cartesian Therapeutics (NASDAQ: RNAC) recently received a number of ratings updates from brokerages and research firms:

• 3/27/2026 – Cartesian Therapeutics had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 3/10/2026 – Cartesian Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $38.00 price target on the stock.
• 3/9/2026 – Cartesian Therapeutics had its “buy” rating reaffirmed by BTIG Research.
• 3/9/2026 – Cartesian Therapeutics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $42.00 price target on the stock.
• 3/9/2026 – Cartesian Therapeutics was upgraded by Cantor Fitzgerald from “neutral” to “overweight”. They now have a $16.00 price target on the stock.

Insider Activity

In other news, CFO Blaine Davis sold 10,591 shares of the company’s stock in a transaction dated Tuesday, January 6th. The stock was sold at an average price of $6.82, for a total transaction of $72,230.62. Following the completion of the transaction, the chief financial officer directly owned 121,220 shares of the company’s stock, valued at $826,720.40. This represents a 8.03% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 60.30% of the stock is owned by corporate insiders.

Cartesian Therapeutics, trading on NASDAQ under the symbol RNAC, is a clinical‐stage biotechnology company specializing in the development of messenger RNA (mRNA)-based therapeutics. The company leverages a proprietary RNA delivery platform to induce the production of therapeutic proteins within patients, aiming to address a range of diseases through in vivo expression of disease-modifying agents. Cartesian’s technology is designed to optimize mRNA stability, translation efficiency and targeted delivery, with potential applications spanning oncology, autoimmune disorders and rare genetic conditions.

At the core of Cartesian’s approach is a synthetic mRNA platform that incorporates proprietary lipid nanoparticle (LNP) formulations.